Navigation Links
Peregrine Pharmaceuticals Forms Anti-Viral Research Group to Oversee Its Anti-PS Infectious Disease Collaborations
Date:10/7/2009

.

Bavituximab is also being tested in Phase II clinical trials for the treatment of advanced breast cancer and non-small cell lung cancer.

Peregrine's work on viral hemorrhagic fevers is funded by the Transformational Medical Technologies Initiative (TMTI) under contract HDTRA1-08-C-0003.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and serious virus infections. The company is pursuing three separate clinical programs in cancer and HCV infection with its lead product candidates bavituximab and Cotara(®). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and bio-manufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the Company will not receive the full $44.4 million awarded under the TMTI program. the risk that bavituximab will not achieve broad-spectrum anti-viral effects and the risk that PS-targeting antibodies will not be less susceptible to viral mutations. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
2. Peregrine Pharmaceuticals Highlights Promising Early Data From Its Three Phase II Bavituximab Cancer Trials
3. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
4. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
5. Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrines Fully Human Anti-PS Antibody in Prostate Cancer Model
6. Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrines PS-Targeting Antibodies
7. Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial
8. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
11. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 According to ... (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise Ball), ... technologies - Global Forecast to 2019" published by ... reach $19,786.3 Million by 2019 from $14,240.0 Million ... 2014 to 2019. Browse 74 market ...
(Date:9/19/2014)... Research and Markets has announced the addition of ... Mental Disorder) Market - Forecast to 2023" report to ... the human microbiome market is segmented by application, disease, product, ... to be valued as $294 million in 2019 and is ... forecast period of 2019-2023. The market is driven by growing ...
(Date:9/19/2014)... FLINT, Mich. , Sept. 19, 2014  Diplomat, ... appointment of David Dreyer to the Board ... an independent director and will also serve as chair ... has almost 30 years of accounting, financial, compliance and ... 2010, Mr. Dreyer has served as chief financial officer, ...
Breaking Medicine Technology:Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3David Dreyer Appointed to Diplomat Board of Directors 2
(Date:9/19/2014)... 20, 2014 Consistent premium price ... the Vision Insurance industry in recent years; however, ... of industry margins. From 2009 to 2014, industry ... provide coverage for routine eye exams and other ... contact lens and refractive surgery. According to IBISWorld ...
(Date:9/19/2014)... Unbound , an international humanitarian organization based ... the Philippines being affected by both a tropical storm and ... to the nearest public schools while others moved to higher ... winds to portions of the northern Philippines. , The ... with more than 10 feet of water. , “It ...
(Date:9/19/2014)... On September 16, Camino Public Relations was ... Top Places to Work in PR Awards Luncheon at ... honorable mentions in two categories for “Multicultural Campaign” and ... Latina voices in the media. , "We're honored to ... of its efforts to improve the national conversation about ...
(Date:9/19/2014)... NH 9/18/14) A leading Dartmouth researcher, working with The ... a paper published today in the Journal of ... increase the risk of melanoma. , "For the first ... length of these telomeres play a part in the ... study Mark Iles, PhD, School of Medicine at the ...
(Date:9/19/2014)... York, New York (PRWEB) September 19, 2014 ... in a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) ... state court next month, Bernstein Liebhard LLP reports. ... in Dallas District Court, the company asserts that claims ... the Texas Civil Practice and Remedies Code, a section ...
Breaking Medicine News(10 mins):Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Vision Insurance in the US Industry Market Research Report from IBISWorld Has Been Updated 4Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2Health News:Camino Public Relations Honored for Raising Latina Voices in National Health Care, Immigration Debates 2Health News:Melanoma risk found to have genetic determinant 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4
... will be a great relief to the parents of Canada’s ... the story, doctors have confirmed //after days of several tests ... twins, known by the names Krista and Tatiana Hogan came ... are four months of age, portray distinct sleep patterns, vision, ...
... and type 2 diabetes increases the risk of death for ... of heart disease deaths by itself, but together they’ve been ... an analysis of more than 900 patients with established coronary ... with both type 2 diabetes and symptoms of depression were ...
... of investigators, by defying the norm. A key enzyme, ... disease, is absent in this strain of gonorrhea. The ... strain, making detection of gonorrhea extremely difficult. ... this odd strain of gonorrhea, was perceived to be ...
... Delhi will continue as a model state in the war ... million kids// below the age of five will be immunized ... Dikshit administered anti-polio drops to a number of children at ... of polio in 2006, an increase from just one case ...
... prevent amputation and restore blood flow in the lower ... gangrene (tissue loss). At eighteen months, the tiny arteries ... success rate, thus preventing amputation. This success rate was ... a six-year period of time. The blockages were caused ...
... no escape into outdoor areas in eateries or distant patios, as ... public. ,The new anti smoking legislation introduced a few ... well as in public doorways, and 'near' the doors, windows and ... , Says Health Minister George Abbott: 'Some people will see it ...
Cached Medicine News:Health News:Combination of Depression and Type-2-diabetes Lethal for Heart Patients 2Health News:Multi-Year Data Shows PAD Treatment Prevents Amputation 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: